Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Children with IgA vasculitis (IgAV) may develop nephritis after initially presenting without kidney involvement. We evaluated whether a cytokine augmentation score (CAS) was associated with improved six-month incident nephritis risk stratification beyond clinical variables and routine inflammatory markers. METHODS: This single-center cohort screened children younger than 18 years with IgAV from January 2023 to June 2024 and used standardized six-month renal outcome ascertainment. Children meeting accepted IgAV classification criteria, with no nephritis during the baseline decision window, complete baseline biomarker data, and six-month renal outcome ascertainment formed the cohort. A routine inflammatory index score (RIIS) summarized z-transformed natural-log C-reactive protein-to-albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII); CAS summarized z-transformed natural-log interleukin (IL)-6, tumor necrosis factor alpha (TNF-α), IL-17A, IL-18, and IL-23. Multivariable logistic regression compared a routine clinical plus RIIS model with a cytokine-augmented model; the area under the receiver operating characteristic curve (AUC), Brier score, calibration, bootstrap optimism correction, decision-curve net benefit, and sensitivity analyses were evaluated. RESULTS: Among 447 screened children, 337 were analyzed; 91 (27.0%) developed incident nephritis. CAS was independently associated with nephritis after adjustment for age, sex, symptom-to-blood-draw interval, gastrointestinal involvement, systolic blood-pressure percentile, subthreshold urinary warning signs, and RIIS (adjusted odds ratio per standard deviation (SD), 2.97; 95% confidence interval (CI), 2.01-4.39; p < 0.001). Adding CAS improved the AUC from 0.724 to 0.801 (Δ0.077; 95% CI, 0.035-0.124; p = 0.001), reduced the Brier score from 0.168 to 0.149, and yielded an optimism-corrected AUC of 0.782. CONCLUSIONS: In this single-center derivation cohort, CAS improved internally evaluated discrimination, Brier score, and risk separation beyond clinical variables and RIIS. The model remains investigational pending external validation, assay standardization, and implementation testing.